C.E.R.A.  en  administración  mensual  corrige  y  mantiene  niveles  estables  de  hemoglobina  en  pacientes  con  enfermedad  renal  crónica no en diálisis: estudio observacional MICENAS II by Martínez Castelao, Alberto et al.
80
originales
http://www.revistanefrologia.com
© 2015 Revista Nefrología. Órgano Oficial de la Sociedad Española de Nefrología
Correspondence: Alberto Martínez Castelao
Servicio de Nefrología.  
Hospital Universitari de Bellvitge. Feixa Llarga, s/n. 08907, Barcelona.
amartinez@bellvitgehospital.cat
albertomcastelao@gmail.com
ABSTRACT
Background and objective: C.E.R.A. (continuous erythropoietin 
receptor activator, pegilated-rHuEPO ß) corrects and maintains 
stable hemoglobin levels in once-monthly administration in 
chronic kidney disease (CKD) patients. The aim of this study was 
to evaluate the management of anemia with C.E.R.A. in CKD 
patients not on dialysis in the clinical setting. Methods: Two 
hundred seventy two anemic CKD patients not on dialysis treated 
with C.E.R.A. were included in this retrospective, observational, 
multicentric study during 2010. Demographical characteristics, 
analytical parameters concerning anemia, treatment data and 
iron status were recorded. Results: C.E.R.A. achieved a good 
control of anemia in both naïve patients (mean Hemoglobin 
11.6g/dL) and patients converted from a previous ESA (mean 
Hemoglobin 11.7g/dL). Most naïve patients received C.E.R.A. 
once monthly during the correction phase and required a low 
monthly dose (median dose 75µg/month). The same median 
dose was required in patients converted from a previous 
ESA, and it was lower than recommended in the Summary of 
Product Characteristics (SPC). Iron status was adequate in 75% 
of anemic CKD patients, but only 50% of anemic patients with 
iron deficiency received iron supplementation. Conclusions: 
C.E.R.A. corrects and maintains stable hemoglobin levels in 
anemic CKD patients not on dialysis, requiring conversion doses 
lower than those recommended by the SPC, and achieving 
target hemoglobin levels with once-monthly dosing frequency 
both in naïve and converted patients.
Keywords: Anemia. Chronic kidney disease (CKD). Erythropoiesis 
stimulating agents. Continuous erythropoietin receptor activator.
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C.E.R.A. en administración mensual corrige y mantiene niveles 
estables de hemoglobina en pacientes con enfermedad renal 
crónica no en diálisis: estudio observacional MICENAS II
RESUMEN
Introducción y objetivo: C.E.R.A. (activador continuo del receptor de 
la eritropoyetina) administrado una vez al mes corrige y mantiene 
estables los niveles de hemoglobina en pacientes con enfermedad 
renal crónica (ERC). Este estudio fue diseñado para evaluar el manejo 
de la anemia con C.E.R.A. en pacientes con ERC no en diálisis (ERC-ND) 
en la práctica clínica. Métodos: Estudio observacional, retrospectivo y 
multicéntrico, llevado a cabo en pacientes con anemia asociada a ERC-
ND en tratamiento con C.E.R.A. durante 2010. Se recogieron datos 
demográficos, parámetros de laboratorio relacionados con la anemia, 
datos del tratamiento y estado del hierro. Resultados: El tratamiento 
con C.E.R.A. logró un buen control de la anemia tanto pacientes naïve 
(hemoglobina media 11,6 g/dl) como en aquellos en conversión desde 
otros agentes estimulantes de la eritropoyesis (hemoglobina media 11,7 
g/dl). La mayoría de los pacientes naïve recibieron C.E.R.A. una vez al mes 
durante el período de corrección y requirieron una dosis mensual baja 
(dosis mediana 75 µg/mes). Las dosis de C.E.R.A. utilizadas en pacientes 
en conversión fueron inferiores a las dosis de conversión recomendadas 
en la ficha técnica. El estatus del hierro fue adecuado en el 75 % de 
aquellos con anemia asociada a ERC-ND, y únicamente el 50 % de los 
pacientes con deficiencia de hierro recibieron suplementos de hierro. 
Conclusiones: En pacientes con anemia asociada a ERC-ND, naïve o en 
conversión, la administración mensual de C.E.R.A. corrige y mantiene 
estables los niveles de hemoglobina, incluso en dosis inferiores a las 
recomendadas en la ficha técnica.
Palabras clave: Anemia. Enfermedad renal crónica. Agentes estimulantes 
de la eritropoyesis. Activador continuo del receptor de la eritropoyetina.
INTRODUCTION
 
Anemia is a frequent complication of chronic kidney 
disease (CKD), mainly related to erythropoietin deficiency. 
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electronic CRF. All patients signed an informed consent 
and the study was approved by the Ethic Committees of all 
participating Hospitals.
 
Selection of patients
 
The study population included adult anemic patients (≥18 years) with CKD stages 3, 4 and 5 (eGFR <60mL/min/1.73m2), not on dialysis and treated with C.E.R.A during at least 6 months, having biochemical and hematological data 
concerning anemia at the beginning of the treatment with C.E.R.A., and with hemoglobin values at 3 and 6 months 
after starting the treatment.
Non compliance with the selection criteria and a need of 
dialysis at the time of the study inclusion were the exclusion 
criteria.
Each investigator gathered data from medical records of all 
patients that had been on treatment with C.E.R.A. for at least 6 months and fulfilled the inclusion criteria.
 
Statistical analysis
 
For description of continuous variables, mean and standard 
deviation were used, while categorical variables were 
described using absolute and relative frequencies. For 
comparison of quantitative variables, parametric tests 
(Student t-test or ANOVA) or non parametric tests (Mann-
Whitney or Kruskall-Wallis) tests were used, as appropriate. 
For comparison of categorical variables, the c2 test was 
performed, with Fisher’s exact test being used when more than 20% of categories had an expected frequency <5. The 
level of statistical significance was established at p<0.05. All statistics were performed using the SAS 9.1.3 software.
 
RESULTS
 
Demographics and baseline characteristics
 Initially, 331 patients were recruited, but 64 patients were 
excluded because of not meeting the inclusion criteria 
(different CKD stage, no anemia or no treated with C.E.R.A., 
no available data of hemoglobin at the beginning of the 
treatment with C.E.R.A., and in two follow-up visits at least). Finally, 267 patients were analyzed (Table 1), most of them were in CKD stages 3 and 4. There were no differences in 
gender across the CKD stages, but patients in CKD stage 4 were older. Diabetes and vascular disease were the most common causes of CKD; and 38.5% of patients had a 
functioning kidney graft. These patients being younger and 
presenting lower body mass index than non-transplant CKD 
patients (Table 2).
Erythropoiesis stimulating agents (ESA) therapy increases 
hemoglobin levels, reduces the need of blood transfusions, improves quality of life (QoL) and regresses left ventricular hypertrophy (LVH).1,2
Despite the efficacy of ESA in the management of renal 
anemia, there are several issues not fully solved, such as the 
appropriate target of hemoglobin level. The European Renal Best Practice guidelines in 2009 recommended a target range of hemoglobin between 11-12g/dL in CKD patients, but individualized according to patients’ age and co-morbidities.3 
However, the publication of the CHOIR,4 CREATE5 and 
TREAT6 studies raised concerns about the safety of targeting to 
higher hemoglobin levels in CKD patients. In fact, recent meta-
analyses have shown that full anemia correction with ESA is 
associated with an increased risk of hypertension, stroke or 
vascular access clotting,7 with minor improvements in QoL,8 and no beneficial effects on LVH,9 as compared to partial anemia 
correction. Several guidelines recommend nowadays a target hemoglobin level of 11-12g/dL with ESA therapy,10,11 whereas the recent KDIGO guidelines advocate for a more restrictive 
use of ESA and lower hemoglobin targets.12 The aim of anemia 
treatment in CKD patients is to partially correct and maintain 
stable hemoglobin levels and within the target range most of 
the time, avoiding hemoglobin fluctuations, and achieving 
the target with the lowest ESA dose possible. To reach these 
objectives, some treatment considerations (frequent anemia 
monitoring, iron supplementation and avoiding frequent ESA 
dose changes) are required.
Despite the similar efficacy and safety of all available ESA, 
some pharmacokinetic and pharmacodynamic differences, 
interval and route of administration and hemoglobin stability 
should be considered while prescribing them to an individual 
patient.
C.E.R.A. is a continuous erythropoietin receptor activator 
created by integrating a large methoxy-polyethylene-glycol-
polymer chain into the erythropoietin molecule,13,14 providing 
new properties to the EPO molecule (faster dissociation from 
the EPO receptor and a longer half-life).15 Since its authorization in Europe in 2007, several studies about C.E.R.A. use in the 
clinical practice in CKD patients not on dialysis have been 
published.16-19 The aim of our study was to evaluate the results 
of anemia treatment with C.E.R.A. in a population of CKD 
patients not on dialysis in the clinical setting.
 
METHODS
 
Study design and data collection
 
This study was a retrospective, multicentric, observational survey carried out in 19 outpatient Nephrology Units in 
Catalonia. Patients were recruited from different Nephrology Units in Catalonia during 2010. Data were collected in an 
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Mean hemoglobin levels before starting ESA treatment was 10.2±0.9g/dL. While 48.2% of the patients were naïve, 51.8% 
had been converted from a previous ESA: erythropoietin beta (n=85, mean monthly dose 16,694±11,180 IU) and darbepoetin alfa (n=50, mean monthly dose 90.5±56.1mg). (Table 3).
The analytical data concerning anemia during C.E.R.A. treatment are shown in Table 4. Naïve patients had lower hemoglobin 
levels before starting C.E.R.A. and hemoglobin increased 
significantly during treatment, while no significant changes in 
hemoglobin were observed in patients converted from a previous ESA (Figure 1). Iron status remained stable during the study.
 
Data concerning anemia treatment with C.E.R.A.
 Most naïve patients (85.1%) started C.E.R.A. treatment in a 
once-monthly schedule, despite that at the time of recruitment 
the recommended dose interval for anemia correction was 
once every two weeks; while almost all converted patients (92.0%) received C.E.R.A. once monthly, as recommended.
The most common dose of C.E.R.A. at the beginning and at the end of the study was 75mg/month, administered 
once monthly. The doses prescribed in converted patients 
were lower than the conversion doses recommended in the Summary of Product Characteristics (SPC) (Table 5).
The initial mean monthly dose of C.E.R.A. in naïve patients corrected by weight was 1.3mg/kg/month, whereas the final 
dose of C.E.R.A. in these patients who achieved hemoglobin levels >11g/dL was 1.1mg/kg/month (Table 6).
Additional treatments for anemia at the start of the study included: iron supplementation (40.7% of patients), folate (12.6%) and vitamin B12 (7.4%). There were no 
significant changes in these percentages at the end of the study (38.5% vs 14% vs 7.3%, respectively). Iron deficiency was diagnosed in 25% of patients (as defined by a serum ferritin <100mg/L or transferrin saturation index [TSAT] <20%), and 45.6% of them did not receive 
iron supplementation.
Mean time since CKD diagnosis was 8.4±8.9 years among 
non-transplanted CKD patients, and mean time since kidney transplantation was 7.1±4.7 years among kidney transplant 
recipients.
 
Anemia data
 Mean time since anemia diagnosis was 4.3±4.1 years and mean time since the beginning of ESA treatment was 3±2.4 years. 
Table 1. Demographical and clinical characteristics  
of patients
Age, years (mean±SD) 66.6±17.4
BMI, kg/m2 (mean±SD) 27.1±4.6
CKD stages, n (%)
Stage 3 108 (40.4)
Stage 4 125 (46.8)
Stage 5 34 (12.7)
Gender, n (%)
Female 139 (52.1)
Male 128 (47.9)
Time since CKD diagnosis, years (mean±SD) 8.4±8.8
Kidney transplantation, n (%) 101 (38.5)
Time since kidney transplantation, years 
(mean±SD)
7.2±4.7
Etiology, n (%)
Diabetic nephropathy 49 (18.4)
Vascular disease 46 (17.2)
Primary glomerulonephritis  33 (12.4)
Pyelonephritis - interstitial nephritis  25 (9.4)
Polycystic kidney disease 25 (5.6)
Hereditary/congenital 6 (2.2)
Systemic disease 4 (1.5)
Unknown 42 (15.7)
Other 39 (14.6)
Table 2. Main characteristics of kidney transplant recipients vs. non-transplanted CKD patients
Transplanted
(Mean±SD)
Non transplanted
(Mean±SD)
Total pa
Age (years) 52.7±15.8 75.8±11.1 66.6±17.4 <0.0001
BMI (kg/m2) 25.5±4.7 28.0±4.4 27.1±4.6 0.0033
C.E.R.A. (µg/month)
Transplanted
(Mean±SD)
Non transplanted
 (Mean±SD)
Total pa
Initial dose 84.1±33.7 87.6±36.8 86.3±35.6 0.1945
Final dose 85.0±47.2 87.3±45.2 86.5±45.8 0.6905
a Mann-Whitney’s U test
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with C.E.R.A in CKD patients not on dialysis is more limited both from randomized controlled trials and in 
the clinical setting.
Mean hemoglobin levels in naïve patients significantly increased by 1.46g/dL from baseline, reaching mean hemoglobin levels of 11.6g/dL; whereas a minimal change of 0.25g/dL was observed in converted patients (from mean hemoglobin levels of 11.5g/dL to 11.7g/dL). The median 
dose of C.E.R.A. required to reach and maintain the target hemoglobin levels was 75µg/month, both in naïve and converted CKD patients not on dialysis. 
Doses that are remarkable similar to those reported in 
the study OASIS in the same population.22
Our results in naïve patients are similar to the results 
of the ARCTOS (dose interval once every 2 weeks),20 CORDATUS (once monthly)21 and SUPRA (once 
monthly) studies,17 and the dose required was similar to 
the recommended in the SPC, supporting its suitability 
also in the clinical setting. It should be noticed that in our study most CKD naïve patients started C.E.R.A. 
on a once-monthly basis, even before the results of the CORDATUS and SUPRA studies were available.17,21
 
DISCUSSION
 
This study demonstrates that C.E.R.A. administered 
once monthly is effective both in correcting and 
maintaining hemoglobin levels in CKD patients not 
on dialysis in the clinical setting. C.E.R.A. at a mean initial dose of 1.3mg/kg/month, similar to the starting 
dose recommended in the SPC, achieved hemoglobin targets in naïve patients. However, the dose required in 
patients converted from previous ESA was lower than 
the recommended in the SPC.
The mean hemoglobin achieved with C.E.R.A. in naïve (11.6g/dL) or converted patients (11.7g/dL) 
was remarkably stable during the observation period, 
and was maintained within the levels recommended by the European Renal Best Practice Guidelines of 2009 (11-12g/dL).11
Several randomized controlled trials in CKD patients 
have demonstrated the efficacy and safety of C.E.R.A. 
in correcting and maintaining appropriate and stable 
hemoglobin levels.20,21 However, most of these trials 
were performed in dialysis patients. Thus, the experience 
Table 3. Treatment with C.E.R.A. in naïve and converted patients
C.E.R.A. (µg/month)
Naïve
(Mean±SD)
Conversion
(Mean±SD)
Total
(Mean±SD)
pa
Initial dose 85.4±36.5 87.2±34.8 86.3±35.6 0.1945
Final dose 81.2±44.4 91.5±46.8 86.5±45.8 0.6905
a Mann-Whitney’s U test.
Note: In one patient final dose for C.E.R.A. was considered missing due to disagreement with the commercially available presentations.
Table 4. Hemoglobin and iron status parameters according to previous use of ESA or not
Initiation with C.E.R.A. 
Naïve
(Mean±SD)
Conversion
(Mean±SD)
Total
(Mean±SD)
pa
Hemoglobin (g/dL) 10.2±0.9 11.5±1.2 10.8±1.3 <0.0001
Fe (µg/mL) 68.7±41.1 59.6±30.6 64.7±37.0 0.4727
Ferritin (ng/mL) 170.4±138.9 163.7±180.7 167.2±159.4 0.2263
TSAT (%) 27.0±19.9 22.7±11.1 25.2±16.8 0.9371
6 Months with C.E.R.A. 
Naïve
(Mean±SD)
Conversion
(Mean±SD)
Total
(Mean±SD)
pa
Hemoglobin (g/dL) 11.6±1.3 11.7±1.4 11.7±1.3 0.5429
Fe (µg/mL) 71.0±43.3 65.0±28.1 68.2±37.0 0.7368
Ferritin (ng/mL) 166.3±140.6 196.1±173.8 180.7±157.6 0.2844
TSAT (%) 25.9±16.3 24.9±12.5 25.5±14.6 0.8059
a Mann-Whitney’s U test.
Documento descargado de http://www.revistanefrologia.com el 09/01/2017. Copia para uso personal, se prohíbe la transmisión de este documento por cualquier medio o formato.
84 Nefrologia 2015;35(1):80-6
Alberto Martínez-Castelao et al. CKD anemia control with C.E.R.A.
originales
Furthermore, in converted patients the dose of C.E.R.A. 
required was lower than the dose recommended in the SPC, 
in agreement with previous studies,16,18,22 confirming that 
the C.E.R.A. dose required to maintain stable hemoglobin 
levels after conversion from shorter acting ESA in non-dialysis CKD patients is lower than 120mg/month.18 
These results deserve further investigation, since the new 
guidelines recommend the use of the lowest ESA dose 
possible to reach the target hemoglobin levels, in order to minimize the risk of adverse events.11,12,23 Thus, this 
finding has potentially relevant clinical and economical 
implications. The OCEANE study also confirmed the 
efficacy and safety of C.E.R.A. in anaemia management 
in CKD patients not on dialysis, with or without a previous 
kidney transplant16. Contrarily to the OCEANE study, in 
our study the doses of C.E.R.A. required were similar 
in CKD patients not on dialysis and kidney transplant 
recipients, despite achieving similar hemoglobin levels 
and iron status.16 Yet, the doses in our kidney transplant 
recipients were similar to those prescribed in the Anemia 
Trans study in Spanish kidney transplant recipients.19
CKD is associated with reduced intestinal iron absorption 
and poor gastrointestinal tolerance to oral iron, thus 
frequently requiring iron supplementation.24 An adequate iron status in order to optimize ESA response is mandatory in anemic CKD patients, in order to optimize erythropoiesis 
and achieve an adequate response to ESA therapy.11,25 In 
iron-deficient patients, therapy with oral or intravenous iron 
reduces ESA dose requirements and increases the probability 
of maintaining hemoglobin levels within the desired target 
range.26 In our study, 75% of patients had an adequate iron 
status, but less than half of patients with iron deficiency 
received iron supplementation. Despite the recent advances 
in iron handling in CKD anemic patients, there is still room 
for improvement in anemia management in this population.
Finally, our study included CKD patients in the clinical 
setting, making our findings broadly applicable to 
usual management of non-dialysis patients.
We recognize the several limitations of this study 
(its retrospective and observational nature, no record 
of several parameters influencing hemoglobin level 
and ESA dose requirements, such as co-morbidities, 
inflammation, malnutrition, iPTH level, use of ACE 
inhibitors and angiotensin II receptor blockers).
Our main conclusion is an adequate management of 
anemia with C.E.R.A. in catalonian CKD patients not 
on dialysis, hemoglobin targets were achieved with 
doses lower than the recommended in the SPC in 
patients converted from shorter-acting ESA, and the 
once-monthly dosing schedule was appropriate both in naïve and converted patients.
Table 5. Treatment with C.E.R.A. according to the Summary of Product Characteristics (SPC)
n=10 n=78 n=43
Previous weekly dose of darbepoetin alpha (µg/week) <40 40-80 >80
Previous weekly dose of epoetin (Ul/week) <8,000 8,000-16,000 16,000
Monthly dose of C.E.R.A. (µg/month) as recommended  
in the C.E.R.A. SPC
120 200 360
Monthly dose of C.E.R.A. (µg/month), median  
(minimum-maximum) 
75 (50-100) 75 (50-150) 100 (30-250)
Monthly dose of C.E.R.A. (µg/month ), mean±SD 72.5±18.4 79.5±22.7 105.0±49.1
Note: In 6 patients the dose for previous ESA was not indicated.
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Figure 1. Mean change in hemoglobin levels (hemoglobin 
at the end minus hemoglobin at the beginning) after 6 
months of treatment according to patients’ status: naïve 
patients or conversion patients.
a Statistically significant differences were observed regarding 
baseline hemoglobin (Student’s t test; p<0.05).
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